Project Grant R01AI192416
- Federal Grant Award Summary The University of Pittsburgh received a $209,408 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 19, 2025 through August 31, 2030. This award supports research focused on characterizing early T cell responses to Mycobacterium tuberculosis (MTB) infection using a non-human primate model. The research deliverables include immunological...
- Federal Project Grant Award Summary The University of Pittsburgh received a $135,586 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026 through March 31, 2028. This award supports the generation of a non-cleavable allele of PIK3IP1/TRIP (Transmembrane Inhibitor of PI3K), a negative regulator of phosphoinositide 3-kinase (PI3K) that is highly expressed in...
- Federal Project Grant Award Summary The University of Pittsburgh received a $413,002 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 24, 2025, with a completion date of June 30, 2027. This award funds research to identify and characterize the protective role of interferon lambda (IFNL) in tuberculosis (TB) infection. The research aims to develop host-directed therapies...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Pittsburgh a $1.13M Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning July 16, 2025 and extending through June 30, 2030. This award supports basic immunological research investigating the development and regulation of the extrafollicular (EF) B cell response as a distinct programmed immune response type. The research aims to...
- Federal Grant Award Summary The University of Pittsburgh received a $2.16 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on April 24, 2026, with a completion date of March 31, 2031. The P-CAPT (PITT Center for Accelerating Phage Therapy) program develops bacteriophage therapy as a medical countermeasure against multidrug-resistant Pseudomonas aeruginosa infections,...
- Federal Grant Award Summary The University of Pittsburgh received a $250,682 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period February 19, 2026 through January 31, 2028. The award supports investigator-initiated biomedical research investigating the role of nuclear paraspeckles in regulating Herpes Simplex Virus 1 (HSV-1) infection in human neurons. The research aims to...
- Federal Grant Award Summary The University of Pittsburgh received a $437,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year project spanning February 1, 2026 through January 31, 2028. This award funds investigator-initiated biomedical research investigating Candida glabrata population diversity during gastrointestinal tract colonization and intra-abdominal candidiasis...
- Federal Project Grant Award Summary The University of Pittsburgh received a $641,889 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2031. This award supports research to develop a molecular taxonomy for immune-mediated diseases, addressing a critical gap in precision medicine by moving beyond clinical phenotype-based disease classification. The...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Pittsburgh a $437,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period February 1, 2026 through January 31, 2028. This research initiative addresses unrecognized azole resistance mechanisms among Candida parapsilosis, a leading cause of bloodstream infections in the United States. The research will characterize...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Pittsburgh a Project Grant totaling $109,076 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period February 14, 2026 through August 31, 2028. The grant supports biomedical research investigating post-transcriptional regulation mechanisms in T cells, specifically examining the role of an RNA-binding protein (RBP) in T cell activation and...
The University of Pittsburgh received a $718,028 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 9, 2026, with a completion date of May 31, 2031. This award supports research to decipher the gating mechanism of intraflagellar transport (IFT) in Trypanosoma brucei, a parasitic protozoan responsible for African trypanosomiasis. The research will employ advanced structural and functional characterization techniques, including cryogenic electron microscopy and magnified expansion microscopy, coupled with mutation phenotype analysis to investigate transition zone components and their role in regulating flagellar protein trafficking in kinetoplastids. The research deliverables will generate foundational scientific knowledge regarding the molecular mechanisms governing IFT complex docking and transit through the transition zone gate in T. brucei. By characterizing these poorly understood mechanisms in this divergent organism, the project aims to advance understanding of flagellar biogenesis, a process essential to parasite motility and transmission. This research supports NIAID's mission to establish and expand biomedical research addressing infectious diseases and related areas, with potential implications for developing novel therapeutic strategies targeting essential biological processes in African trypanosomiasis.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $718.0k | 6/10/26 |